How I treat mucormycosis

Blood

Volumn 118, Issue 5, 2011, Pages 1216-1224

  Kontoyiannis, Dimitrios P ^a,b   Lewis, Russell E ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BUSULFAN; CASPOFUNGIN; CIMETIDINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFERASIROX; DEFEROXAMINE; ECHINOCANDIN; ESOMEPRAZOLE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; OMEPRAZOLE; POSACONAZOLE; RAPAMYCIN; RIFAMPICIN; RIFAMYCIN; TACROLIMUS; VINCA ALKALOID; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; CLINICAL FEATURE; COMORBIDITY; DEBRIDEMENT; DECISION MAKING; DRUG BIOAVAILABILITY; DRUG MONITORING; DRUG POTENTIATION; EARLY DIAGNOSIS; HEMATOLOGY; HUMAN; HYPERBARIC OXYGEN; INFECTION CONTROL; IRON OVERLOAD; LONG TERM CARE; MINIMUM INHIBITORY CONCENTRATION; MUCORALES; MUCORMYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; RELAPSE; SALVAGE THERAPY; SECONDARY PREVENTION;

EID: 80051558724     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-316430     Document Type: Article

References (83)

1. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-569. (Pubitemid 40995116)
2. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-53. (Pubitemid 41170352)
3. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am. 2006;20(3):581-607. (Pubitemid 44375113)
4. Kontoyiannis DP, Lewis RE. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases (6th ed), Vol 2. Philadelphia, PA: Elsevier Churchill Livingstone; 2005:2973.
5. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350-1360.
6. Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis. 2009;15(9):1395-1440.
7. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265-273.
8. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503-509.
9. Kontoyiannis DP, Wessel VC, Bodey GP, et al. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30(6):851-856. (Pubitemid 32250321)
10. Stefanini M, Allegra S. Pulmonary mucormycosis in acute histiocytic leukemia. N Engl J Med. 1957;256(22):1026-1030.
11. Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis. 2006;25(4):215-229. (Pubitemid 43800540)
12. Antoniadou A. Outbreaks of zygomycosis in hospitals. Clin Microbiol Infect. 2009;15(5):55-59.
13. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica. 2006;91(7):986-989. (Pubitemid 44023159)
14. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236-301. (Pubitemid 30205427)
15. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection Clin Infect Dis. 2008;47(8):1041-1050.
16. Gaziev D, Baronciani D, Galimberti M, et al. Mucormycosis after bone marrow transplantation: report of four cases in thalassemia and review of the literature. Bone Marrow Transplant. 1996;17(3):409-414.
17. Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of role of iron overload in pathogenesis. Bone Marrow Transplant. 1999;24(3):307-312. (Pubitemid 29377872)
18. Sujobert P, Boissel N, Bergeron A, et al. Breakthrough zygomycosis following empirical caspofungin treatment: report of two patients with leukemia and literature review. Open J Hematol. 2010;1-3.
19. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007;40(5):451-456. (Pubitemid 47288224)
20. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004;64(18):1997-2020. (Pubitemid 39280370)
21. Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect. 2009;15(50):93-97.
22. Viscoli C, Castagnola E. Geoclimatic factors and invasive aspergillosis after allogeneic hematopoietic stem cell transplantation: new perspectives for patient management? Clin Infect Dis. 2010;50(12):1598-1600.
23. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111- 5118.
24. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41(1):60-66. (Pubitemid 40863745)
25. Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis. 2008;46(11):1733-1737. (Pubitemid 351706772)
26. Wong PW, Stefanec T, Brown K, White DA. Role of fine-needle aspirates of focal lung lesions in patients with hematologic malignancies. Chest. 2002;121(2):527-532. (Pubitemid 34132994)
27. Gupta S, Sultenfuss M, Romaguera JE, et al. CT-guided percutaneous lung biopsies in patients with haematologic malignancies and undiagnosed pulmonary lesions. Hematol Oncol. 2010;28(2):75-81.
28. Sampsonas F, Kontoyiannis DP, Dickey BF, Evans SE. Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study. Cancer. 2011 Jan 18 [Epub ahead of print].
29. Shannon VR, Andersson BS, Champlin RE, Kontoyiannis DP. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45(4):647-655.
30. Lass-Florl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis. 2007;45(7):e101-e104. (Pubitemid 47580399)
31. Larone DH. Medically Important Fungi: A Guide to Identification (3rd ed). Washington, DC: ASM Press; 1995:105-119.
32. Ben-Ami R, Luna M, Lewis RE, Walsh TJ, Kontoyiannis DP. A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. J Infect. 2009;59(2):134-138.
33. Tarrand JJ, Lichterfeld M, Warraich I, et al. Diagnosis of invasive septate mold infections: a correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol. 2003;119(6):854-858. (Pubitemid 37047847)
34. Kontoyiannis DP, Chamilos G, Hassan SA, et al. Increased culture recovery of Zygomycetes under physiologic temperature conditions. Am J Clin Pathol. 2007;127(2):208-212. (Pubitemid 46797177)
35. Alvarez E, Sutton DA, Cano J, et al. Spectrum of zygomycete species identified in clinically significant specimens in the United States. J Clin Microbiol. 2009;47(6):1650-1656.
36. Kasai M, Harrington SM, Francesconi A, et al. Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol. 2008;46(11):3690-3702.
37. Dannaoui E, Schwarz P, Slany M, et al. Molecular detection and identification of zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) evaluation. J Clin Microbiol. 2010;48(6):2043-2046.
38. Schwarz P, Bretagne S, Gantier JC, et al. Molecular identification of zygomycetes from culture and experimentally infected tissues. J Clin Microbiol. 2006;44(2):340-349. (Pubitemid 43222220)
39. Ibrahim AS, Gebremariam T, Fu Y, et al. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52(4):1556-1558. (Pubitemid 351522035)
40. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbitalcerebral mucormycosis. Clin Infect Dis. 2008;47(3):364-71. (Pubitemid 352009357)
41. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48(12):1743-1751.
42. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53(5):2223-2224.
43. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother. 2006;50(6):1993-1999. (Pubitemid 43807517)
44. Nagappan V, Deresinski S. Posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis. 2007;45(12):1610-1617. (Pubitemid 351411847)
45. Jain R, Pottinger P. The effect of gastric acid on the absorption of posaconazole. Clin Infect Dis. 2008;46(10):1627. (Pubitemid 351706748)
46. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007;27(12):1627-1636. (Pubitemid 350234311)
47. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289-1297. (Pubitemid 46717290)
48. Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother. 2010;54(3):1298-1304.
49. Lekakis LJ, Lawson A, Prante J, et al. Fatal Rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature. Biol Blood Marrow Transplant. 2009;15(8):991-995.
50. Kishel JJ, Sivik J. Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up. J Oncol Pharm Pract. 2008;14(4):189-193.
51. Almyroudis NG, Sutton DA, Fothergill AW, et al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother. 2007;51(7):2587-2590. (Pubitemid 47047341)
52. Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother. 2005;49(2):721-727. (Pubitemid 40175685)
53. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50(1):126-133. (Pubitemid 43042912)
54. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42:e61-e65.
55. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26(6):1383-1396. (Pubitemid 28270170)
56. Nucci M, Perfect JR. When primary antifungal therapy fails. Clin Infect Dis. 2008;46(9):1426-1433. (Pubitemid 351589944)
57. Miceli MH, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer. 2007;110(1):112-120. (Pubitemid 46986424)
58. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med. 1999;159(12):1301-1309. (Pubitemid 29293592)
59. Ojeda-Uribe M, Herbrecht R, Kiefer MH, et al. Lessons from a case of oromandibular mucormycosis treated with surgery and combination of amphotericin B lipid formulation plus caspofungin. Acta Haematol. 2010;124(2):98-102.
60. Tedder M, Spratt JA, Anstadt MP, et al. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994;57(4):1044-1050. (Pubitemid 24133513)
61. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003;362(9398):1828-1838. (Pubitemid 37494764)
62. Ibrahim AS, Edwards JE Jr, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother. 2006;58(5):1070.
63. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes. 1982;31(12):1109-1114. (Pubitemid 13242245)
64. Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies. J Clin Invest. 1993;91(5):1979-1986. (Pubitemid 23141469)
65. Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008;21(6):620-625.
66. John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect. 2005;11(7):515-517. (Pubitemid 40895150)
67. Kaide CG, Khandelwal S. Hyperbaric oxygen: applications in infectious disease. Emerg Med Clin North Am. 2008;26(2):571-595. (Pubitemid 351491562)
68. Hubel K, Dale DC, Engert A, et al. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis. 2001;183(2):321-328. (Pubitemid 32066035)
69. Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J. 2004;23(8):769-773. (Pubitemid 39063294)
70. Hubel P, Dale DC, Liles WC. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases. J Infect Dis. 2002;185(10):1490-1501.
71. Gil-Lamaignere C, Simitsopoulou M, Roilides E, et al. Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis. 2005;191(7):1180-1187. (Pubitemid 40404378)
72. Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Med Mycol. 2008;46(1):23-29. (Pubitemid 351298237)
73. Moussett S, Hermann S, Klein SA, et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol. 2005;84(11):734-741. (Pubitemid 41447808)
74. Pagano L, Akova M, Dimopoulos G, et al. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66(l):i5-i14.
75. Pagano L, Girmenia C, Mele L, et al. Infections caused by filamentous fungi in patients with hematologic malignancies: a report of 391 cases by GIMEMA Infection Program. Haematologica. 2001;86(8):862-870. (Pubitemid 32847449)
76. Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, nonrhizopus, -mucor, and -lichtheimia species. Clin Microbiol Rev. 2011;24(2):411-445.
77. Kontoyiannis DP. Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success. Bone Marrow Transplant. 2011;46(2):165-173.
78. Yokoe D, Casper C, Dubberke E, et al. Safe living after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44(8):509-519.
79. Kamei K. Mycopathologia animal models of zygomycosis: Absidia, Rhizopus, Rhizomucor, and Cunninghamella. Mycopathologia. 2001;152(1):5-13. (Pubitemid 32984102)
80. Chamilos G, Lewis RE, Hu J, et al. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A. 2008;8(105):9367-9372.
81. Ma LJ, Ibrahim AS, Skory C, et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet. 2009;5(7):e1000549.
82. Liu M, Spellberg B, Phan Q, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010;120(6):1914-1924.
83. Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis. 2008;47(2):226-235. (Pubitemid 351952889)